Literature DB >> 27212695

Ductal carcinoma in situ diagnosed by breast needle biopsy: Predictors of invasion in the excision specimen.

S C Doebar1, C de Monyé2, H Stoop3, J Rothbarth4, S P Willemsen5, C H M van Deurzen3.   

Abstract

BACKGROUND: A substantial proportion of women with a pre-operative diagnosis of pure ductal carcinoma in situ (DCIS) has a final diagnosis of invasive breast cancer (IBC) after surgical excision and, consequently, a potential indication for lymph node staging. The aim of our study was to identify novel predictors of invasion in patients with a needle-biopsy diagnosis of DCIS that would help us to select patients that may benefit from a sentinel node biopsy (SNB). PATIENTS AND METHODS: We included 153 patients with a needle-biopsy diagnosis of DCIS between 2000 and 2014, which was followed by surgical excision. Several pre-operative clinical, radiological and pathological features were assessed and correlated with the presence of invasion in the excision specimen. Features that were significantly associated with upstaging in the univariable analysis were combined to calculate upstaging risks.
RESULTS: Overall, 22% (34/155) of the patients were upstaged to IBC. The following risk factors were significantly associated with upstaging: palpability, age ≤40 years, mammographic mass lesion, moderate to severe periductal inflammation and periductal loss of decorin expression. The upstaging-risk correlated with the number of risk factors present: e.g. 9% for patients without risk factors, 29% for patients with 1 risk factor, 37% for patients with 2 risk factors and 54% for patients with ≥3 risk factors.
CONCLUSION: The identified risk factors may be helpful to predict the upstaging-risk for patients with a needle-biopsy diagnosis of pure DCIS, which facilitates the performance of a selective SNB for high-risk patients and avoid this procedure in low-risk patients.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Breast; Ductal carcinoma in situ; Needle biopsy; Prediction of invasion

Mesh:

Year:  2016        PMID: 27212695     DOI: 10.1016/j.breast.2016.02.014

Source DB:  PubMed          Journal:  Breast        ISSN: 0960-9776            Impact factor:   4.380


  5 in total

1.  Comparison of HER2 amplification status among breast cancer subgroups offers new insights in pathways of breast cancer progression.

Authors:  Kathleen Lambein; Mieke Van Bockstal; Lies Vandemaele; Rudy Van den Broecke; Veronique Cocquyt; Sofie Geenen; Hannelore Denys; Louis Libbrecht
Journal:  Virchows Arch       Date:  2017-05-31       Impact factor: 4.064

Review 2.  A retrospective alternative for active surveillance trials for ductal carcinoma in situ of the breast.

Authors:  Mieke R Van Bockstal; Marie C Agahozo; Linetta B Koppert; Carolien H M van Deurzen
Journal:  Int J Cancer       Date:  2019-05-08       Impact factor: 7.396

3.  Application of deep learning to predict underestimation in ductal carcinoma in situ of the breast with ultrasound.

Authors:  Lang Qian; Zhikun Lv; Kai Zhang; Kun Wang; Qian Zhu; Shichong Zhou; Cai Chang; Jie Tian
Journal:  Ann Transl Med       Date:  2021-02

4.  Pathological underestimation and biomarkers concordance rates in breast cancer patients diagnosed with ductal carcinoma in situ at preoperative biopsy.

Authors:  Hemei Zhou; Jing Yu; Xiaodong Wang; Kunwei Shen; Jiandong Ye; Xiaosong Chen
Journal:  Sci Rep       Date:  2022-02-09       Impact factor: 4.379

5.  The prognostic significance of immune microenvironment in breast ductal carcinoma in situ.

Authors:  Michael S Toss; Asima Abidi; Dorothea Lesche; Chitra Joseph; Sakshi Mahale; Hugo Saunders; Tanjina Kader; Islam M Miligy; Andrew R Green; Kylie L Gorringe; Emad A Rakha
Journal:  Br J Cancer       Date:  2020-03-17       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.